中文名稱:BML-277 | 英文名稱:BML-277 |
CAS:516480-79-8 | 品牌: 一研 |
保存條件: Store at -20°C | 產(chǎn)品類別: 抑制劑 |
Cas : 516480-79-8 |
產(chǎn)品屬性:
產(chǎn)品名稱 | 規(guī)格 | CAS號 | 型號 |
BML-277 | 10mM (in 1mL DMSO) 10mg 50mg | 516480-79-8 | EY-Y0165445 |
Cas No.516480-79-8
別名
化學(xué)名 2-[4-(4-chlorophenoxy)phenyl]-3H-benzimidazole-5-carboxamide
分子式 C20H14ClN3O2
分子量 363.8
溶解度 ≥ 18.2mg/mL in DMSO
儲存條件 Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request
產(chǎn)品描述:
BML-277 has shown the ATP-competitive inhibition of chk2 with the Ki value of 37nM. BML-277 has also been exhibited to be a chk2 inhibitor with the IC50 value of 15±6.9nM and efficiently rescue T-cell populations from the apoptosis of radiation-induced in a concentration-dependent fashion with the EC50 of 3~7.6μM. The Km of ATP for chk2 is 99μM and assuming that intracellular ATP concentration is 10mM. Apart from these, BML-277 has shown the inhibition through docking into a homology model of chk2 ATP binging site [1].
References:
[1]Arienti KL1, Brunmark A, Axe FU, McClure K, Lee A, Blevitt J, Neff DK, Huang L, Crawford S, Pandit CR, Karlsson L, Breitenbucher JG. Checkpoint kinase inhibitors: SAR and radioprotective properties of a series of 2-arylbenzimidazoles. J Med Chem. 2005 Mar 24;48(6):1873-85.
成立日期 | 2014-06-05 (11年) | 注冊資本 | 100 |
員工人數(shù) | 50-100人 | 年?duì)I業(yè)額 | ¥ 100萬以內(nèi) |
主營行業(yè) | 生化試劑,抗體,細(xì)胞培養(yǎng),分子生物學(xué),免疫安全 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價(jià)格 | 公司名稱 | 報(bào)價(jià)日期 | |
---|---|---|---|---|
詢價(jià) |
VIP6年
|
上海澤葉生物科技有限公司
|
2024-12-26 | |
¥155 |
VIP3年
|
TargetMol中國(陶術(shù)生物)
|
2024-12-12 | |
詢價(jià) |
VIP7年
|
臺州市科瑞生物技術(shù)有限公司
|
2024-12-11 | |
¥930.00 |
VIP1年
|
上海阿拉丁生化科技股份有限公司
|
2024-11-29 |